Pharma Exports Jumped 12.43% During April-December 2021

New Delhi: India’s exports of pharmaceutical products during April-December 2020-21 grew by 12.43 per cent to USD 17.57 billion, Parliament was informed on Friday in reply to unstarred question No. 248.

India’s exports of pharmaceutical products have not declined and they are growing consistently, Minister of State for Commerce and Industry Hardeep Singh Puri said in a written reply to the Rajya Sabha.

“During 2019-20, India’s exports of pharmaceuticals were USD 20.58 billion with a growth rate of 7.57 per cent over the previous year. Total pharma exports during April-December 2020-21 were at USD 17.57 billion, registering a growth rate of 12.43 per cent over the same period of the previous year,” he said.

Replying to a question on FDI, Minister of State for Commerce and Industry Som Parkash said that during the last three years, the Foreign Direct Investment (FDI) equity inflow increased from USD 44.85 billion in 2017-18 to USD 49.97 billion in 2019-20.

According to the data, FDI in defence industries stood at USD 0.63 million. It was USD 2.20 million in 2019-20.

The retail trading sector attracted USD 1.26 billion in April-November 2020-21 period, while telecommunications received USD 19.65 million.

In reply to a separate query, Parkash said total FDI inflow in terms of percentage of GDP has increased from 2.21 per cent (2009-10 to 2013-14) to 2.41 per cent (2014-15 to 2018-19).

On a question about single window approval system for industry, Parkash said the central government is working on setting up a Single Window System for clearances and approvals of industry in the country.

Despite the presence of several IT platforms for investing in India such as in departments of the Government of India and State Single Window Clearances, investors need to visit multiple platforms to gather information and obtain clearances from different stakeholders, he said.

“To address this, the creation of a Centralized Investment Clearance Cell, which would provide end-to-end facilitation support, including pre-investment advisory, information related to land banks and facilitating clearances at central and state level was proposed,” Parkash added.

The cell, he said, is being planned as a one-stop digital platform to obtain all requisite central and state clearances/ approvals required to start business operations in India.

The cell “will be a National portal that integrates the existing clearance systems of the various ministries/ departments of Government of India and of state governments without disruption to the existing IT portals of ministries and will have a single, unified application form,” the minister added.

This will eliminate the need for investors to visit multiple platforms/ offices to gather information and obtain clearances from different stakeholders and provide time-bound approvals and real time status update to investors, Parkash informed.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’